Dec. 23 at 3:31 AM
$OSRH re-read last paragraph 👇
💪 💪 💪
Emerging Growth Research has released a flash report on OSR Holdings Inc. (NASDAQ: OSRH), reaffirming its Buy-Emerging rating and setting a 12-month price target of
$10.00, representing a potential 1,487% upside from the company's recent closing price.
The report highlights a significant non-binding licensing term sheet between OSR Holdings and BCM Europe AG, valued at
$815 million, for the global development and commercialization of OSRH's oral T-cell immunotherapy program, VXM01.
The agreement, which includes an expected
$20 million upfront payment in 2026 and subsequent milestone payments, is seen as a major validation of OSR Holdings' strategy and management. The research also notes increased likelihood of deal completion and strong cash flow prospects beginning in 2026, positioning OSRH for further potential growth.
